Journal Information
Vol. 43. Issue 11.
Pages 636-639 (January 2007)
Share
Share
Download PDF
More article options
Vol. 43. Issue 11.
Pages 636-639 (January 2007)
Case Report
Full text access
Polymyositis and Interstitial Lung Disease With a Favorable Response to Corticosteroids and Methotrexate
Visits
7633
Nieves Hoyosa, Álvaro Casanovaa, Silvia Sáncheza, Claudia Valenzuelaa, Asunción Garcíab, Rosa María Giróna,
Corresponding author
med002861@nacom.es

Correspondence: Dr. R.M. Girón. Servicio de Neumología. Hospital Universitario de La Princesa. Diego de León, 62. 28006 Madrid. España
a Servicio de Neumología, Hospital de La Princesa, Madrid, Spain
b Servicio de Anatomía Patológica, Hospital de La Princesa, Madrid, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Polymyositis is a rare collagen disease that can involve the lungs. Between 5% and 30% of patients with polymyositis present interstitial lung disease at diagnosis or during the course of disease. Onset is usually insidious and involves dyspnea and nonproductive cough. Several histopathological findings are associated with polymyositis and the most common is nonspecific interstitial pneumonia. The prognosis of interstitial lung disease associated with polymyositis is better than that of idiopathic pulmonary fibrosis, since most patients respond to treatment with corticosteroids and immunosuppressants.

We report the case of a 60-year-old woman with dyspnea and muscle weakness who was diagnosed with polymyositis and interstitial lung disease (radiography indicated possible nonspecific interstitial pneumonia). The patient responded well to prednisone and methotrexate.

Key words:
Polymyositis
Lung diseases
interstitial
Nonspecific interstitial pneumonia

La polimiositis es una colagenopatía rara, que puede afectar al pulmón. Entre un 5 y un 30% de los pacientes con polimiositis presenta una enfermedad pulmonar intersticial en el momento del diagnóstico o durante el curso de la enfermedad. El inicio suele ser insidioso en forma de disnea y tos seca. Son varias las entidades histopatológicas que se asocian a polimiositis, de las cuales la más frecuente es la neumonía intersticial no específica. El pronóstico de la enfermedad pulmonar intersticial difusa asociada a polimiositis es mejor que el de la fibrosis pulmonar idiopática, ya que la mayoría de los pacientes responde al tratamiento con glucocorticoides e inmunodepresores.

Presentamos el caso clínico de una mujer de 60 años con síntomas de disnea y debilidad muscular, a quien se diagnosticó de polimiositis y enfermedad pulmonar intersticial difusa (posible neumonía intersticial no específica por hallazgos radiológicos), y que mostró buena respuesta al tratamiento con prednisona y metotrexato.

Palabras clave:
Polimiositis
Enfermedad pulmonar intersticial difusa
Neumonía intersticial no específica
Full text is only aviable in PDF
References
[1]
ES Mills, WH Matthews.
Interstitial pneumonitis in dermatopolymyositis.
JAMA, 160 (1956), pp. 1467-1470
[2]
G Salmeron, SD Greenberg, MD Lidsky.
Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings.
Arch Intern Med, 141 (1981), pp. 1005-1010
[3]
I Marie, PY Hatron, E Hachulla, B Wallaert, U Michon-Pasturel, B Devulder.
Pulmonary involvement in polymyositis and in dermatomyositis.
J Rheumatol, 26 (1999), pp. 1336-1343
[4]
H Kourakata, T Takada, E Suzuki, K Enomoto, I Saito, Y Taguchi, et al.
Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia.
Respirology, 4 (1999), pp. 223-228
[5]
HD Tazelaar, RW Viggiano, J Pickersgill, TV Colby.
Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.
Am Rev Respir Dis, 141 (1990), pp. 727-733
[6]
American Thoracic Society (ATS)/European Respiratory Society.
International multidisciplinary consensus classification of the idiopathic interstitial pneumonias.
Am J Respir Crit Care Med, 165 (2002), pp. 277-304
[7]
WW Douglas, HD Tazelaar, TE Hartman, RP Hartman, PA Decker, DR Schroeder.
Polymyositis-dermatomyositis-associated interstitial lung disease.
Am J Respir Crit Care Med, 164 (2001), pp. 1182-1185
[8]
M Mino, S Noma, Y Taguchi, K Tomii, Y Kohri, K Oida.
Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT.
AJR Am J Roentgenol, 169 (1997), pp. 83-87
[9]
M Akira, H Hara, M Sakatani.
Interstitial lung disease in association with polymyositis-dermatomyositis: long term follow-up CT evaluation in seven patients.
[10]
J Ikezoe, T Johkoh, N Kohno, N Takeuchi, K Ichikado, H Nakamura.
High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis.
J Thorac Imaging, 11 (1996), pp. 250-259
[11]
S Yoshida, M Akizuki, T Mimori, H Yamagata, S Inada, M Homma.
The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis.
Arthritis Rheum, 26 (1983), pp. 604-611
[12]
RM Bernstein, SH Morgan, J Chapman, CC Bunn, MB Mathews, M Turner-Warwick.
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease.
Br Med J, 289 (1984), pp. 151-152
[13]
CC Mok, CH To, ML Szeto.
Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine.
Scand J Rheumatol, 32 (2003), pp. 181-183
[14]
T Shinohara, T Hidaka, Y Matsuki, T Ishizuka, M Takamizawa, M Kawakami, et al.
Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy.
Intern Med, 36 (1997), pp. 519-523
[15]
TW Bunch, JW Worthington, JJ Combs, DM Ilstrup, AG Engel.
Azathioprine with prednisone for polymyositis. A controlled, clinical trial.
Ann Intern Med, 92 (1980), pp. 365-369
[16]
TW Bunch.
Prednisone and azathioprine for polymyositis: long-term followup.
Arthritis Rheum, 24 (1981), pp. 45-48
[17]
HK Chang, DH Lee.
Successful combination therapy of cyclosporine and methotrexate for refractory polymyositis with anti-Jo-1 antibody: a case report.
J Korean Med Sci, 18 (2003), pp. 131-134
[18]
S Ochi, T Nanki, K Takada, F Suzuki, Y Komano, T Kubota, et al.
Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.
Clin Exp Rheumatol, 23 (2005), pp. 707-710
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?